{"analyses":[{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.85","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","paramType":"Hazard Ratio (HR)","paramValue":"0.71","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"6","value":"5.5"},{"groupId":"OG001","lowerLimit":"6","upperLimit":"8","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"294"}],"units":"Participants"}],"description":"The median time, in months, from the date of randomization to the date of a PFS event. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received fluorouracil 800 mg/m\\^2 IV on Days 1 through 5 of cycle every 3 weeks for 6 cycles. Participants also received cisplatin 80 mg/m\\^2, IV, on Day 1 of cycle every 3 weeks for 6 cycles; as well as, capecitabine 1000 mg/m\\^2, PO, twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.","id":"OG000","title":"Fluoropyrimidine, Cisplatin"},{"description":"Participants received an initial loading dose of trastuzumab 8 mg/kg, IV, on Day 1 of cycle, followed by 6 mg/kg, IV, every 3 weeks until disease progression. Participants also received fluorouracil 800 mg/m\\^2 IV on Days 1 through 5 of cycle every 3 weeks for 6 cycles; cisplatin 80 mg/m\\^2 IV on Day 1 of cycle every 3 weeks for 6 cycles; and capecitabine 1000 mg/m\\^2 PO twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.","id":"OG001","title":"Trastuzumab, Fluoropyrimidine, Cisplatin"}],"paramType":"MEDIAN","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis","title":"Progression-Free Survival - Time to Event","type":"SECONDARY","unitOfMeasure":"months"}